These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20942844)

  • 1. Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.
    Finch DK; Midha A; Buchanan CL; Cochrane D; Craggs RI; Cruwys S; Grahames C; Kolbeck R; Lowe DC; Maltby J; Pattison DV; Vousden KA; Ward A; Sleeman MA; Mallinder PR
    Br J Pharmacol; 2011 Jan; 162(2):480-90. PubMed ID: 20942844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation.
    Ota N; Takase M; Uchiyama H; Olsen SK; Kanagawa O
    J Immunol; 2010 Nov; 185(10):6041-8. PubMed ID: 20926799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
    Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
    J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
    Votavova P; Tomala J; Kovar M
    Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.
    Meghnem D; Morisseau S; Frutoso M; Trillet K; Maillasson M; Barbieux I; Khaddage S; Leray I; Hildinger M; Quéméner A; Jacques Y; Mortier E
    J Immunol; 2017 Jun; 198(12):4563-4568. PubMed ID: 28507024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.
    Tamzalit F; Barbieux I; Plet A; Heim J; Nedellec S; Morisseau S; Jacques Y; Mortier E
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8565-70. PubMed ID: 24912180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
    Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
    Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha.
    Bouchaud G; Garrigue-Antar L; Solé V; Quéméner A; Boublik Y; Mortier E; Perdreau H; Jacques Y; Plet A
    J Mol Biol; 2008 Sep; 382(1):1-12. PubMed ID: 18656487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.
    Chenoweth MJ; Mian MF; Barra NG; Alain T; Sonenberg N; Bramson J; Lichty BD; Richards CD; Ma A; Ashkar AA
    J Immunol; 2012 May; 188(9):4149-57. PubMed ID: 22447977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.
    Chertova E; Bergamaschi C; Chertov O; Sowder R; Bear J; Roser JD; Beach RK; Lifson JD; Felber BK; Pavlakis GN
    J Biol Chem; 2013 Jun; 288(25):18093-103. PubMed ID: 23649624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.
    Wu Z; Xue HH; Bernard J; Zeng R; Issakov D; Bollenbacher-Reilley J; Belyakov IM; Oh S; Berzofsky JA; Leonard WJ
    Blood; 2008 Dec; 112(12):4411-9. PubMed ID: 18796634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.
    Rowley J; Monie A; Hung CF; Wu TC
    J Immunol; 2008 Dec; 181(12):8237-47. PubMed ID: 19050240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.
    Elpek KG; Rubinstein MP; Bellemare-Pelletier A; Goldrath AW; Turley SJ
    Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21647-52. PubMed ID: 21098276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice.
    Thi VAD; Jeon HM; Park SM; Lee H; Kim YS
    Mol Cells; 2019 Dec; 42(12):869-883. PubMed ID: 31760731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
    Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
    Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
    Guo S; Smeltz RB; Nanajian A; Heller R
    Front Immunol; 2020; 11():614667. PubMed ID: 33628206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.
    Shi Y; Dincheva-Vogel L; Ayemoba CE; Fung JP; Bergamaschi C; Pavlakis GN; Farzaneh F; Gaensler KML
    Blood Adv; 2018 Nov; 2(22):3177-3192. PubMed ID: 30482760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.
    Robinson TO; Hegde SM; Chang A; Gangadharan A; Rivas S; Madakamutil L; Zalevsky J; Miyazaki T; Schluns KS
    J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
    Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
    Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.